齐拉西酮联合抗抑郁药物治疗难治性抑郁症对照研究的Meta分析

目的评价齐拉西酮联合抗抑郁药物与抗抑郁药物单一治疗难治性抑郁症的差异。方法应用循证医学方法对符合纳入标准的8项研究进行分析，评价齐拉西酮联合抗抑郁药物与抗抑郁药物单一治疗难治性抑郁症的症状学变化、有效率、痊愈率的差异。结果齐拉西酮组症状评分显著低于对照组（z=15．84，P〈0．01，加权均数差=-3．83．95％可信区间-4．30～3．36）。有效率和痊愈率均显著高于对照组（63.3％VS．45．7％，Z=4.31，P〈0．0001，比值比2．25，95％可信区间1．56～3．26；35．6％VS．19．1％，Z=4．44，P〈0．00001，比值比2．58，95％可信区间1．70～3．91）。结论齐拉西酮联合抗抑郁药物可以提高治疗难治性抑郁症的疗效。

Meta-Analysis of Difference between Olanzapine Combining Antidepressant and Single Antidepressant in Treatment of Depression

Objective To assess the difference in changes of symptoms, effective rate and full remission rate between Ziprasidone combining antidepressants and single antidepressant in the treatment of treatment-resistant depression （TRD）. Methods 8 studies meeting our criteria were analyzed by evidence-based medicine, comparing the difference in changes of symptoms, efficacy rate and full remission rate. Results The lower depressive symptoms in Ziprasidone group comparing controls were found （Z=15.84, P〈0.01, WMD=-3.83, 95%CI -4.30--3.36）. The very significant higher effective rate and full remission rate in Ziprasidone group comparing controls were found （63.3% vs. 45.7%, Z=4.31, P〈0.000 1, OR=2.25, 95%CI 1.56~3.26; 35.6% vs. 19.1%, Z=4.44, P〈0.000 01, OR=2.58, 95%CI 1.70-3.91 ）. Conclusion It can promote therapeutic efficacy of patients with treatment-resistant depression, combining antidepressants with Ziprasidone.